Drug Profile
Tenofovir amibufenamide - Jiangsu Hansoh Pharmaceutical
Alternative Names: Hengmu; HS-10234Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Amines; Antivirals; Phosphorus compounds; Propionates; Purines; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 10 Nov 2023 Updated efficacy data from a phase III trial in Hepatitis B presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases (ASLD-2023)
- 25 Apr 2022 No development reported - Phase-III for Hepatitis B (Treatment-experienced) in China (PO) (Hansoh Pharma website, April 2022)
- 25 Apr 2022 No development reported - Phase-III for Hepatitis B (Treatment-naive) in China (PO) (Hansoh Pharma website, April 2022)